Dynamics of SARS-CoV-2 IgG antibodies and neutralising antibodies in rheumatic and musculoskeletal diseases patients with COVID-19
Authors' conclusion
GC and anti-rheumatic medications can potentially alter the production of specific antibodies, especially NAb, in RMD patients post-COVID-19 infection.
Study context
- Population
- Rheumatic and musculoskeletal diseases (RMD) patients and healthy controls after COVID-19 infection
- Participants
- 292 vs 104
- Exposure
- RMD patients vs healthy controls
- RMDn = 292
- Healthy controls (HC)n = 104reference
- Outcome
- Anti-S1/S2 IgG and NAb levels by chemiluminescent immunoassay
- Follow-up
- 60 and 90 days post-COVID-19 infection
Methodological detailslogistic regression
- Logistic regression
Main finding
As reported in the abstract
Anti-S1/S2 IgG and NAb levels
- Anti-S1/S2 IgG levels relatively stable; Neutralising antibodies (NAb) levels in RMD could vary greatly between days 60 and 90
- RMD vs HC: P < 0.001
Observational data: associations, not effects.
Further findings
Risk factors for reduced anti-S1/S2 IgG and NAb levels (logistic regression)
- Prior glucocorticoids (GC), immunosuppressants and b/tsDMARDs independent risk factors, irrespective of RMD subtype
Original publication
Dynamics of SARS-CoV-2 IgG antibodies and neutralising antibodies in rheumatic and musculoskeletal diseases patients with COVID-19. Clin Exp Rheumatol. Published 12 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →